{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:19:49Z","timestamp":1785550789695,"version":"3.56.0"},"reference-count":38,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grifols","award":["FIS PI19\/00753"],"award-info":[{"award-number":["FIS PI19\/00753"]}]},{"name":"Instituto de Salud Carlos III","award":["FIS PI19\/00753"],"award-info":[{"award-number":["FIS PI19\/00753"]}]},{"name":"Deutsche Jos\u00e9 Carreras Leuk\u00e4mie Stiftung e.V","award":["FIS PI19\/00753"],"award-info":[{"award-number":["FIS PI19\/00753"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>A Delphi-based survey was designed to assess the opinions of clinical hematologists (n = 17) and clinical immunologists (n = 18) from across Spain on secondary immunodeficiencies (SID) in the management of oncohematological patients. There was 100% agreement on the need to have available guidelines for the management of immunodeficiency in hematological patients; to perform a baseline immunological evaluation in patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), lymphoma and hematopoietic stem cell transplantation (HSCT) recipients; and to quantify serum IgG, IgA and IgM levels when SID is suspected. More than 90% agreed on the need for active immunization against seasonal influenza and H1N1, pneumococcus and Haemophilus influenzae. There was a consensus on the monitoring of IgG levels every 3 months (83%) and the need to have available a clinical protocol for the use of IVIG in the management of SID (94%), to monitor trough IgG levels to determine the correct IVIG dose (86%) and to discontinue IVIG after the recovery of IgG levels after 12 months of follow-up (77%). The findings of the present survey may be useful recommendations for hematologists and immunologists to improve the management of SID in daily practice.<\/jats:p>","DOI":"10.3390\/jcm12196356","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T11:58:57Z","timestamp":1696420737000},"page":"6356","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations"],"prefix":"10.3390","volume":"12","author":[{"given":"Concepci\u00f3n","family":"Boqu\u00e9","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Duran i Reynals, Institut Catal\u00e0 d\u2019Oncologia, 08908 Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9585-6167","authenticated-orcid":false,"given":"Silvia","family":"S\u00e1nchez-Ram\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Instituto de Medicina de Laboratorio, Hospital Cl\u00ednico San Carlos, Universidad Complutense, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7654-8836","authenticated-orcid":false,"given":"Ra\u00fal","family":"C\u00f3rdoba","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fundaci\u00f3n Jimenez Diaz University Hospital, Health Research Institute-Fundaci\u00f3n Jimenez Diaz, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Moreno","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital de la Santa Creu i Sant Pau, Josep Carreras Leukaemia Research Institute, Universitat Aut\u00f3noma de Barcelona, 08025 Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cabezudo","sequence":"additional","affiliation":[{"name":"Service of Hematology, ICO-Hospital de Sant Joan Desp\u00ed Mois\u00e8s Broggi, 08970 Sant Joan Desp\u00ed, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7861\/clinmedicine.16-6-571","article-title":"Secondary antibody deficiency\u2014Causes and approach to diagnosis","volume":"16","author":"Srivastava","year":"2016","journal-title":"Clin. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/hon.2921","article-title":"On the relevance of immunodeficiency evaluation in haematological cancer","volume":"39","author":"Chapel","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1053\/j.seminoncol.2005.12.013","article-title":"Infectious Complications of Chronic Lymphocytic Leukemia","volume":"33","author":"Wadhwa","year":"2006","journal-title":"Semin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","article-title":"Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin?","volume":"34","author":"Dhalla","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/bjh.13455","article-title":"Poor functional antibody responses are present in nearly all patients with chronic lymphocytic leukaemia, irrespective of total IgG concentration, and are associated with increased risk of infection","volume":"171","author":"Parry","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Drug Therapy: Multiple Myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"New Engl. J. Med."},{"key":"ref_7","first-page":"e930241-1","article-title":"Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g\/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China","volume":"27","author":"Ye","year":"2021","journal-title":"Experiment"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.iac.2018.08.001","article-title":"Personalized Therapy","volume":"39","author":"Wasserman","year":"2019","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000363445","article-title":"Immunoglobulin Replacement Therapy: A Twenty-Year Review and Current Update","volume":"164","author":"Saeedian","year":"2014","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.intimp.2017.09.005","article-title":"Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach","volume":"52","author":"Pecoraro","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: A practical approach","volume":"188","author":"Jolles","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: A review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/ejh.13580","article-title":"Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus","volume":"106","author":"Jolles","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_14","unstructured":"European Medicines Agency (2022, February 25). Guideline on Core SmPC for Human Normal Immunoglobulin Administration. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-rev-6_en.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3389\/fimmu.2019.00586","article-title":"The ID-Signal Onco-Haematology Group Primary and Secondary Immunodeficiency Diseases in Oncohaematology: Warning Signs, Diagnosis, and Management","volume":"10","author":"Sastre","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.coi.2019.09.004","article-title":"B cell targeted therapies in autoimmune disease","volume":"61","author":"Barnas","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/10600280211058754","article-title":"Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations","volume":"56","author":"Arnall","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","article-title":"Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma","volume":"34","author":"Abramson","year":"2020","journal-title":"Transfus. Med. Rev."},{"key":"ref_19","first-page":"1","article-title":"CAR-T cell combination therapy: The next revolution in cancer treatment","volume":"22","author":"Tondok","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kozaki, R., Vogler, M., Walter, H.S., Jayne, S., Dinsdale, D., Siebert, R., Dyer, M.J.S., and Yoshizawa, T. (2018). Responses to the selective Bruton\u2019s Tyrosine Kinase (BTK) inhibitor tirabrutinib (ONO\/GS-4059) in Diffuse large B-cell lymphoma cell lines. Cancers, 10.","DOI":"10.3390\/cancers10040127"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/ACM.0000000000001812","article-title":"The Use of the Delphi and Other Consensus Group Methods in Medical Education Research: A Review","volume":"92","author":"Varpio","year":"2017","journal-title":"Acad. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"738915","DOI":"10.3389\/fimmu.2021.738915","article-title":"Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia","volume":"12","author":"Allegra","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/cid\/cir492","article-title":"Infections in Patients With Hematologic Neoplasms and Hematopoietic Stem Cell Transplantation: Neutropenia, Humoral, and Splenic Defects","volume":"53","author":"Safdar","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hon.2323","article-title":"Secondary immunodeficiency in lymphoproliferative malignancies","volume":"34","author":"Friman","year":"2016","journal-title":"Hematol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5114\/ceji.2020.101265","article-title":"Secondary immunodeficiencies with predominant antibody deficiency: Multidisciplinary perspectives of Polish experts","volume":"45","author":"Siedlar","year":"2020","journal-title":"Central Eur. J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/10245332.2018.1538001","article-title":"The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: A prospective study from 21 French hematology departments","volume":"24","author":"Benbrahim","year":"2019","journal-title":"Hematology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.13223","article-title":"Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies","volume":"102","author":"Na","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101020","DOI":"10.1016\/j.blre.2022.101020","article-title":"Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel","volume":"58","author":"Jolles","year":"2022","journal-title":"Blood Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.clml.2023.05.008","article-title":"Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma","volume":"23","author":"Giralt","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cei\/uxac070","article-title":"British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy","volume":"210","author":"Grigoriadou","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ochoa-Grull\u00f3n, J., Guevara-Hoyer, K., L\u00f3pez, C.P., de Diego, R.P., Cortijo, A.P., Polo, M., Morales, M.M., Mandley, E.A., Garc\u00eda, C.J., and Bola\u00f1os, E. (2022). Combined Immune Defect in B-Cell Lymphoproliferative Disorders Is Associated with Severe Infection and Cancer Progression. Biomedicines, 10.","DOI":"10.3390\/biomedicines10082020"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","article-title":"Interventions to reduce infections in patients with hematological malignancies: A systematic review and meta-analysis","volume":"7","author":"Chai","year":"2023","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Klein, E.-M., Sauer, S., Klein, S., Tichy, D., Benner, A., Bertsch, U., Brandt, J., Kimmich, C., Goldschmidt, H., and M\u00fcller-Tidow, C. (2021). Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Cancers, 13.","DOI":"10.3390\/cancers13143439"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.2013.101261","article-title":"Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: A single-center experience in 61 patients","volume":"99","author":"Compagno","year":"2014","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.21873\/anticanres.12712","article-title":"Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis","volume":"38","author":"Dimou","year":"2018","journal-title":"Anticancer. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/19\/6356\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:05:01Z","timestamp":1760130301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/19\/6356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":38,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["jcm12196356"],"URL":"https:\/\/doi.org\/10.3390\/jcm12196356","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]}}}